Franklin K - Search Results

1

Chronic Fatigue and Postexertional Malaise in People Living With Long COVID: An Observational Study.

Twomey R, DeMars J, Franklin K, Culos-Reed SN, Weatherald J, Wrightson JG. Twomey R, et al. Among authors: franklin k. Phys Ther. 2022 Apr 1;102(4):pzac005. doi: 10.1093/ptj/pzac005. Phys Ther. 2022. PMID: 35079817 Free PMC article.

2

"I feel like my body is broken": exploring the experiences of people living with long COVID.

Wurz A, Culos-Reed SN, Franklin K, DeMars J, Wrightson JG, Twomey R. Wurz A, et al. Among authors: franklin k. Qual Life Res. 2022 Dec;31(12):3339-3354. doi: 10.1007/s11136-022-03176-1. Epub 2022 Jul 11. Qual Life Res. 2022. PMID: 35816258 Free PMC article.

3

Inhibition of oxytocin-induced but not angiotensin-induced rat uterine contractions following exposure to sodium sulfide.

Hayden LJ, Franklin KJ, Roth SH, Moore GJ. Hayden LJ, et al. Among authors: franklin kj. Life Sci. 1989;45(26):2557-60. doi: 10.1016/0024-3205(89)90239-7. Life Sci. 1989. PMID: 2559275

4

Angiotensin 'antipeptides': (-)messenger RNA complementary to human angiotensin II (+)messenger RNA encodes an angiotensin receptor antagonist.

Moore GJ, Ganter RC, Franklin KJ. Moore GJ, et al. Among authors: franklin kj. Biochem Biophys Res Commun. 1989 May 15;160(3):1387-91. doi: 10.1016/s0006-291x(89)80157-3. Biochem Biophys Res Commun. 1989. PMID: 2471521

5

A new approach to angiotensin antagonists: methylation of the tyrosine hydroxyl in angiotensin II.

Scanlon MN, Matsoukas JM, Franklin KJ, Moore GJ. Scanlon MN, et al. Among authors: franklin kj. Life Sci. 1984 Jan 23;34(4):317-21. doi: 10.1016/0024-3205(84)90618-0. Life Sci. 1984. PMID: 6546405

6

Evaluation of azidobenzoyl and benzoylbenzoyl groups for photoaffinity labelling of angiotensin receptors in responding tissues.

Moore GJ, Pollock B, Ganter R, Franklin K. Moore GJ, et al. Among authors: franklin k. Proc West Pharmacol Soc. 1990;33:261-4. Proc West Pharmacol Soc. 1990. PMID: 2274543 No abstract available.

7

Importance of the N-terminal domain of the type I angiotension II antagonist [Sar1,Ile8]ANG II for receptor blockade.

Moore GJ, Ganter RC, Goghari MH, Franklin KJ. Moore GJ, et al. Among authors: franklin kj. Int J Pept Protein Res. 1991 Jul;38(1):1-7. doi: 10.1111/j.1399-3011.1991.tb01401.x. Int J Pept Protein Res. 1991. PMID: 1938100

8

Influence of methylation of the histidine ring of [Sar1]angiotensin II on conformation and biological activity.

Moore GJ, Goghari MH, Franklin KJ. Moore GJ, et al. Among authors: franklin kj. Int J Pept Protein Res. 1993 Nov;42(5):445-9. doi: 10.1111/j.1399-3011.1993.tb00152.x. Int J Pept Protein Res. 1993. PMID: 8106195

9

Therapeutic quotient for some angiotensin antagonists determined from antagonist and agonist activities in rat pressor assays.

Franklin KJ, Moore GJ. Franklin KJ, et al. Proc West Pharmacol Soc. 1987;30:313-6. Proc West Pharmacol Soc. 1987. PMID: 3628297 No abstract available.

10

Structure-activity relationships for the competitive angiotensin antagonist [sarcosine,O-methyltyrosine4]angiotensin II (sarmesin).

Goghari MH, Franklin KJ, Moore GJ. Goghari MH, et al. Among authors: franklin kj. J Med Chem. 1986 Jun;29(6):1121-4. doi: 10.1021/jm00156a035. J Med Chem. 1986. PMID: 3754902

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

643 results

Search Page

Filters